BR112014010823A2 - anticorpos gp41 neutralizantes e seus usos - Google Patents

anticorpos gp41 neutralizantes e seus usos

Info

Publication number
BR112014010823A2
BR112014010823A2 BR112014010823A BR112014010823A BR112014010823A2 BR 112014010823 A2 BR112014010823 A2 BR 112014010823A2 BR 112014010823 A BR112014010823 A BR 112014010823A BR 112014010823 A BR112014010823 A BR 112014010823A BR 112014010823 A2 BR112014010823 A2 BR 112014010823A2
Authority
BR
Brazil
Prior art keywords
antibodies
hiv
nucleic acids
disclosed
neutralizing
Prior art date
Application number
BR112014010823A
Other languages
English (en)
Other versions
BR112014010823B1 (pt
Inventor
Zhang Baoshan
Nabel Gary
Ofek Gilad
Georgiev Ivelin
Zhu Jiang
Huang Jinghe
R Mascola John
B Laub Leo
Connors Mark
Kwong Peter
S Rudicell Rebecca
Yang Yongping
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of BR112014010823A2 publication Critical patent/BR112014010823A2/pt
Publication of BR112014010823B1 publication Critical patent/BR112014010823B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/161—HIV-1, HIV-2 gag-pol, e.g. p55, p24/25, p17/18, p.7, p6, p66/68, p51/52, p31/34, p32, p40

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • AIDS & HIV (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)

Abstract

neutralizing gp41 antibodies and their use abstract monoclonal neutralizing antibodies are disclosed that specifically bind to the hiv-1 gp41 membrane-proximal external region (mper). also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. the antibodies and compositions disclosed herein can be used for detecting the presence of hiv-1 in a biological sample, or detecting an hiv-1 infection or diagnosing aids in a subject. in additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an hiv infection. thus, disclosed are methods of treating and/or preventing hiv infection. tradução do resumo resumo patente de invenção: "anticorpos gp41 neutralizantes e seus usos". anticorpos neutralizantes monoclonais são descritos, que especificamente se ligam à região externa próxima da membrana de gp41 de hiv-1 (mper). são também descritas composições incluindo os anticorpos que especificamente ligam gp41, ácidos nucléicos codificando estes anticorpos, vetores de expressão incluindo os ácidos nucléicos, e células hospedeiras isoladas que expressam os ácidos nucléicos. os anticorpos e composições descritos aqui podem ser usados para detectar a presença de hiv-1 em uma amostra biológica, ou detectar uma infecção por hiv-1 ou diagnosticar aids em um indivíduo. além disso, o amplo espaço de neutralização dos anticorpos descritos torna-os ideais para o tratamento de um indivíduo com uma infecção por hiv. desse modo, são descritos métodos de tratamento e/ou infecção por hiv.
BR112014010823-4A 2011-11-07 2012-11-07 anticorpos que se ligam a gp41 e neutralizam o vírus da imunodeficiência humana tipo 1 (hiv-1), seus usos, molécula de ácido nucleico, vetor de expressão, composição, kit, bem como métodos de detecção de infecção pelo hiv-1 e de teste de imunógeno potencial BR112014010823B1 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161556660P 2011-11-07 2011-11-07
US61/556,660 2011-11-07
US201261672708P 2012-07-17 2012-07-17
US61/672,708 2012-07-17
US201261698480P 2012-09-07 2012-09-07
US61/698,480 2012-09-07
US201261702703P 2012-09-18 2012-09-18
US61/702,703 2012-09-18
PCT/US2012/063958 WO2013070776A1 (en) 2011-11-07 2012-11-07 Neutralizing gp41 antibodies and their use

Publications (2)

Publication Number Publication Date
BR112014010823A2 true BR112014010823A2 (pt) 2017-09-12
BR112014010823B1 BR112014010823B1 (pt) 2021-02-17

Family

ID=48290514

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014010823-4A BR112014010823B1 (pt) 2011-11-07 2012-11-07 anticorpos que se ligam a gp41 e neutralizam o vírus da imunodeficiência humana tipo 1 (hiv-1), seus usos, molécula de ácido nucleico, vetor de expressão, composição, kit, bem como métodos de detecção de infecção pelo hiv-1 e de teste de imunógeno potencial

Country Status (7)

Country Link
US (4) US9475862B2 (pt)
EP (1) EP2776463B1 (pt)
CN (1) CN104080805B (pt)
BR (1) BR112014010823B1 (pt)
RU (1) RU2624046C2 (pt)
WO (1) WO2013070776A1 (pt)
ZA (1) ZA201403264B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11357866B2 (en) * 2013-04-03 2022-06-14 The Administrators Of The Tulane Educational Fund Expression of HIV inhibitors by mesenchymal stem cells
WO2015017755A1 (en) * 2013-08-02 2015-02-05 The Regents Of The University Of California Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
WO2016123569A2 (en) * 2015-01-29 2016-08-04 Plantvax, Inc. Highly expressed protective plant-derived broadly neutralizing hiv monoclonal antibodies for use in passive immunotherapy
CA2979708A1 (en) * 2015-03-19 2016-09-22 Duke University Hiv-1 neutralizing antibodies and uses thereof
US11071783B2 (en) * 2015-03-19 2021-07-27 Duke University HIV-1 neutralizing antibodies and uses thereof
WO2016168758A1 (en) 2015-04-17 2016-10-20 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
CN104830908B (zh) * 2015-06-02 2018-04-10 中国食品药品检定研究院 假病毒包装系统及其用途
AU2016347058B2 (en) 2015-10-25 2023-11-09 Sanofi Trispecific and/or trivalent binding proteins for prevention or treatment of HIV infection
WO2017079479A1 (en) * 2015-11-03 2017-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Neutralizing antibodies to hiv-1 gp41 and their use
US10730933B2 (en) 2015-12-05 2020-08-04 Centre Hospitalier Universitaire Vaudois HIV binding agents
KR101873815B1 (ko) * 2016-03-04 2018-07-03 (주)진매트릭스 재조합 단백질의 가용화를 위한 조성물, 그 방법 및 이를 이용한 재조합 항원의 생산 방법
KR20180134378A (ko) 2016-04-13 2018-12-18 사노피 3특이성 및/또는 3가 결합 단백질
SI3443006T1 (sl) 2016-04-13 2024-01-31 Sanofi Trispecifični in/ali trivalentni vezni proteini
CN105801694A (zh) * 2016-05-03 2016-07-27 上海科新生物技术股份有限公司 一种抗心磷脂/β2糖蛋白I复合物的嵌合抗体
WO2018002902A1 (en) 2016-07-01 2018-01-04 Glaxosmithkline Intellectual Property (No.2) Limited Antibody-drug conjugates and therapeutic methods using the same
WO2018053328A1 (en) * 2016-09-16 2018-03-22 Duke University Bispecific molecules comprising an hiv-1 envelope targeting arm
CN107383190B (zh) * 2017-08-03 2020-09-25 深圳市慢性病防治中心 人源抗HIV gp41特异性抗体及其应用
JP7036909B2 (ja) 2017-10-10 2022-03-15 サノフイ 抗ｃｄ３８抗体および使用方法
SG11202012043RA (en) 2018-07-03 2021-01-28 Gilead Sciences Inc Antibodies that target hiv gp120 and methods of use
EP3864043A1 (en) 2018-10-09 2021-08-18 Sanofi Trispecific anti-cd38, anti-cd28, and anti-cd3 binding proteins and methods of use for treating viral infection
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
TW202104274A (zh) 2019-04-09 2021-02-01 法商賽諾菲公司 用於治療ｈｉｖ感染之三特異性及／或三價結合蛋白
WO2020247366A1 (en) * 2019-06-05 2020-12-10 University Of Georgia Research Foundation Compositions and methods for preventing or treating human immunodeficiency virus associated pulmonary arterial hypertension
AU2020315598A1 (en) 2019-07-16 2022-03-03 Gilead Sciences, Inc. HIV vaccines and methods of making and using
US20220283161A1 (en) * 2019-07-25 2022-09-08 The Johns Hopkins University Methods and compositions for hepatitis c virus (hcv)
CN114651003A (zh) 2019-09-10 2022-06-21 黑曜石疗法公司 用于可调调节的ca2-il15融合蛋白
WO2021076559A1 (en) * 2019-10-14 2021-04-22 The Scripps Research Institute Human broadly neutralizing antibodies against the membrane-proximal external region of hiv env for vaccine design and intervention
CN111253493B (zh) * 2020-03-05 2021-03-23 武汉科技大学 一种靶向hiv病毒囊膜双位点的嵌合抗原受体及其表达载体和应用
US20230056252A1 (en) 2020-08-25 2023-02-23 Gilead Sciences, Inc. Multi-specific antigen binding molecules targeting hiv and methods of use
US20230303666A1 (en) * 2020-09-24 2023-09-28 The Broad Institute, Inc. Cell-free antibody engineering platform and neutralizing antibodies for sars-cov-2
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
IL313306A (en) 2021-12-17 2024-08-01 Viiv Healthcare Co Combined treatments for HIV infections and their uses
WO2024015741A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
CN118091132B (zh) * 2024-03-07 2024-10-22 杭州安旭生物科技股份有限公司 用于检测hiv的免疫层析检测装置和试剂盒

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005052139A2 (en) 2003-11-19 2005-06-09 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Method of inducing memory b cell development and terminal differentiation
US8147840B2 (en) * 2004-05-14 2012-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human immunodeficiency virus (HIV) immunization strategies employing conformationally-stabilized, surface-occluded peptides comprising a gp41 2F5 epitope in association with lipid
RU2393873C2 (ru) * 2005-05-02 2010-07-10 Майметикс Корпорейшн Антитело или его фрагмент, имеющие нейтрализующую активность в отношении вич, но не в отношении il2
JP5020941B2 (ja) 2005-05-02 2012-09-05 マイメティクス コーポレーション Ｈｉｖに対して中和活性を有するがｉｌ２には中和活性を有さない抗体又はその断片
US8945857B2 (en) * 2005-07-01 2015-02-03 John Schrader Methods of isolating cells and generating monoclonal antibodies
EP1997830A1 (en) * 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
CA2738176C (en) * 2008-09-23 2012-01-10 Hema-Quebec Method for polyclonal immunoglobulin g production by human b cells
EA025275B1 (ru) * 2009-02-06 2016-12-30 Майметикс Корпорейшн Способ, терапевтическая композиция, вакцинная комбинация и набор для терапевтического или профилактического лечения вич
US20110064760A1 (en) * 2009-08-14 2011-03-17 Cho Michael W Polypeptides comprising epitopes of hiv gp41 and methods of use
AU2010298025B2 (en) 2009-09-25 2016-04-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use
WO2011046623A2 (en) * 2009-10-16 2011-04-21 Duke University Hiv-1 antibodies
EP2316920A1 (en) * 2009-10-30 2011-05-04 BioNTech AG Clonal expansion of B cells
WO2011085247A2 (en) * 2010-01-08 2011-07-14 Immusoft Corporation Vectors and methods for transducing b cells
US20110212106A1 (en) * 2010-01-20 2011-09-01 Institute For Research In Bioscience Hiv-1 neutralizing antibodies and uses thereof
WO2013163427A1 (en) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection

Also Published As

Publication number Publication date
US20180002406A1 (en) 2018-01-04
CN104080805B (zh) 2017-02-22
EP2776463A1 (en) 2014-09-17
US20160333076A1 (en) 2016-11-17
RU2624046C2 (ru) 2017-06-30
EP2776463B1 (en) 2017-09-20
EP2776463A4 (en) 2015-03-25
US20140342407A1 (en) 2014-11-20
RU2014118462A (ru) 2015-12-20
US9475862B2 (en) 2016-10-25
CN104080805A (zh) 2014-10-01
US10047148B2 (en) 2018-08-14
BR112014010823B1 (pt) 2021-02-17
ZA201403264B (en) 2017-08-30
WO2013070776A8 (en) 2014-06-12
US10047147B2 (en) 2018-08-14
WO2013070776A1 (en) 2013-05-16
US20140348785A1 (en) 2014-11-27
US9783595B2 (en) 2017-10-10

Similar Documents

Publication Publication Date Title
BR112014010823A2 (pt) anticorpos gp41 neutralizantes e seus usos
Meng et al. SARS-CoV-2 Omicron spike mediated immune escape and tropism shift
CO2018009434A2 (es) Anticuerpos monoclonales de proteína ns1 anti-virus del dengue
BR112015019066A2 (pt) Anticorpos humanos para proteína f do vírus respiratório sincicial e métodos de uso dos mesmos
MX2020004578A (es) Composiciones de casz y metodos de uso.
BR112016027805A2 (pt) receptores de células t do anti-papilomavírus humano 16 e7
BR112014018331A8 (pt) Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação
BR112014015152A2 (pt) métodos e materiais para a avaliação da perda de heterozigosidade
BR122020006914B8 (pt) Anticorpo de domínio único anti-tnf-alfa e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
BRPI0806185A2 (pt) anticorpo neutralizador de alta potência, fragmento de um anticorpo, molécula de ácido nucléico, vetor, célula, clone de célula b imortalizado, epìtopo, polipeptìdio imunogênico, método para produção de anticorpos, composição farmacêutica, uso de um primeiro anticorpo ou fragmento, composição ou uso, método para tratamento de um sujeito, kit para diagnóstico de infecção por hcmv, método para preparação de uma célula recombinante, método para produção de anticorpos, método de detecção de polipeptìdios e epìtopo que se liga especificamente a um anticorpo
BR112016006929A2 (pt) Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
EA201590184A1 (ru) Вакцина на основе микобактериальных антигенов
BR112014010718A2 (pt) métodos e sistemas para detecção de analito em amostra
BR112012019881A2 (pt) proteínas de domínio estrutural baseadas na fibronectina que ligam-se à il-23
WO2006123256A3 (en) Hivcon: an hiv immunogen and uses thereof
AR082149A1 (es) Anticuerpos contra el virus sincicial respiratorio (rsv) humano y metodos para su uso
BR112013002993A2 (pt) métodos e composições para prevenção de uma condição
AR066396A1 (es) Anticuerpos anti-r7v y usos de los mismos
BR112014024282A2 (pt) anticorpos ligantes ao receptor b1 da bradicinina
BR112018006006A2 (pt) receptores de antígeno, cadeias peptídicas, células recombinantes, métodos para produzir uma célula que expressa um receptor de antígeno e para o tratamento de uma doença, ácidos nucleicos e composição farmacêutica
MX2014011504A (es) Metodos para la deteccion de anticuerpos neutralizantes anticitomegalovirus.
BR112014023063A2 (pt) anticorpos que neutralizam rsv, mpv e pvm e usos dos mesmos
WO2012018907A3 (en) Polypeptides for treating and/or limiting influenza infection
BR112015021341A2 (pt) anticorpos neutralizantes de flavivírus e métodos de uso dos mesmos
Ren et al. Characterization of SARS-CoV-2 variants B. 1.617. 1 (Kappa), B. 1.617. 2 (Delta) and B. 1.618 on cell entry, host range, and sensitivity to convalescent plasma and ACE2 decoy receptor

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07E Notice of approval relating to section 229 industrial property law

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure
B07A Technical examination (opinion): publication of technical examination (opinion)
B09A Decision: intention to grant
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/11/2012, OBSERVADAS AS CONDICOES LEGAIS.